Skip to main content

. 1982 Aug 14;285(6340):475. doi: 10.1136/bmj.285.6340.475

Regression of carcinoid tumour with cyproheptadine.

A L Harris, I E Smith

PMCID: PMC1499232 PMID: 6809131

475

Images in this article

p475-a
on p.475

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Allison D. J., Modlin I. M., Jenkins W. J. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet. 1977 Dec 24;2(8052-8053):1323–1325. doi: 10.1016/s0140-6736(77)90369-5. [DOI] [PubMed] [Google Scholar]
Bonomi P., Hovey C., Dainauskas J. R., Slayton R., Wolter J. Management of carcinoid syndrome. Med Pediatr Oncol. 1979;6(1):77–83. doi: 10.1002/mpo.2950060111. [DOI] [PubMed] [Google Scholar]
Hill G. J. Carcinoid tumors: pharmacological therapy. Oncology. 1971;25(4):329–343. doi: 10.1159/000224582. [DOI] [PubMed] [Google Scholar]
Richardson P. D., Withrington P. G. A comparison of the effects of bradykinin, 5-hydroxytryptamine and histamine on the hepatic arterial and portal venous vascular beds of the dog: histamine H1 and H2-receptor populations. Br J Pharmacol. 1977 May;60(1):123–133. doi: 10.1111/j.1476-5381.1977.tb16756.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Tutton P. J., Steel G. G. Influence of biogenic amines on the growth of xenografted human colorectal carcinomas. Br J Cancer. 1979 Nov;40(5):743–749. doi: 10.1038/bjc.1979.255. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES